| Patents for C07C 59 - Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups oh, o-metal, cho, keto, ether, groups, groups, or groups (14,643) |
|---|
| 03/13/2008 | WO2008030618A1 Benzo-fused compounds for use in treating metabolic disorders |
| 03/13/2008 | WO2008008718A3 Cyclopentane derivatives as antiglaucoma agents |
| 03/13/2008 | WO2007130890A3 Cyclopentane-derivatives and their use as ocular hypotensive agents |
| 03/13/2008 | US20080064747 Prevention of Neutrophil Recruitment |
| 03/13/2008 | US20080064661 Dihydroxyl compounds and compositions for cholesterol management and related uses |
| 03/13/2008 | US20080064660 Modulation of Inflammation Related to Columnar Epithelia |
| 03/13/2008 | DE19701208B4 Magnetische Flüssigkeit auf Fluorbasis Magnetic liquid fluorine-based |
| 03/12/2008 | EP1897541A2 Hypoglycemic agent |
| 03/12/2008 | EP1414809B1 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
| 03/12/2008 | CN101142164A Method for producing optically active 3-phenylpropionic acid derivatives and follow-on products of the latter |
| 03/12/2008 | CN101139281A Nano calcium lactate and method for making same |
| 03/06/2008 | WO2008026707A1 Perfluorocarboxylic acid salt and method for producing the same |
| 03/06/2008 | WO2008026422A1 Compound, positive-type resist composition, and method for formation of resist pattern |
| 03/06/2008 | WO2007149829A3 Therapeutic compounds |
| 03/06/2008 | US20080058414 Substituted Cyclopentanes Or Cyclopentanones As Therapeutic Agents |
| 03/06/2008 | US20080058412 1-(4-((R,S)-5-[1,2]dithiolan-3-ylpentyloxy)-3,5-dimethylphenyl)-3-(4-carboxydimethylmethyloxy-3,5-dimethylphenyl)prop-2-en-1-one; peroxisome proliferator activated receptor agonist; lipid or glucose metabolism: hyperlipidemia, diabetes, obesity; dermatologicalal: psoriasis, atopic dermatitis, acne |
| 03/06/2008 | US20080058321 Benzothiazin-3-one compound and intermediate therefor |
| 03/05/2008 | EP1894912A1 Process for producing racemic 3-hydroxy-3-(2-phenylethyl) hexanoic acid ester |
| 03/05/2008 | EP1894911A1 Vitamin d-like compound |
| 03/05/2008 | EP1894910A1 Method for producing glycolic acid |
| 03/05/2008 | CN100372829C Novel shogaol compound and tyrosinase activity inhibitor comprising the compound |
| 03/04/2008 | US7339073 Method for obtaining 5-halogenolaevulinic acid alkyl esters |
| 03/04/2008 | US7338977 for the treatment of viral infection, particularly HIV-1 infection; non-brominated, partially alkylated pyrogallol calixarene type compounds and derivatives thereof |
| 03/04/2008 | US7338960 {[2-Methyl-4-({[4'-(trifluoromethyl)-3-biphenylyl]methyl}thio)phenyl]oxy}acetic acid; adipogenic signalling cascade and lipid homeostasis; increase High Density Lipoproteins; hypotensive agent; Syndrome X, obesity, insulin resistance, cardiovascular disorder |
| 02/28/2008 | WO2008024892A2 Cyclic 11-beta hydroxysteroid dehydrogenase type i inhibitors |
| 02/28/2008 | US20080051411 choline fenofibrate, or fenofibric acid salts of ethanolamine, diethanolamine, piperazine, calcium or tromethamine; salts have improved photostability; hyperlipidemia or coronary heart diseases |
| 02/28/2008 | CA2661401A1 Cyclic 11-beta hydroxysteroid dehydrogenase type i inhibitors |
| 02/27/2008 | EP1891026A2 Cycloalkylidene compounds as selective estrogen receptor modulators |
| 02/27/2008 | EP1891020A2 Processes for the preparation of azoxystrobin using dabco as a catalyst and novel intermediates used in the processes |
| 02/27/2008 | EP1890990A1 Method for making carboxylic acids |
| 02/27/2008 | EP1317409B1 Method for the purification of an alpha-hydroxy acid on an industrial scale |
| 02/27/2008 | CN101133011A Process for the manufacture of substituted propionic acids |
| 02/27/2008 | CN101130492A Method for purifying calcium gluconate solution |
| 02/27/2008 | CN100371074C Novel catalytic formulation and its preparation method |
| 02/26/2008 | US7335799 administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X |
| 02/26/2008 | US7335689 for example, 6,9-Dihydroxy-2,2,13,13-tetramethyl-tetradecanedioic acid, 2,2,13,13-Tetramethyl-tetradecane-1,6,9,14-tetraol, 6,10-Dihydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid; treatment of Alzheimer's Disease, metabolic syndrome disorder, cancer, cardiovascular disease, diabetic nephropathy |
| 02/21/2008 | WO2008021054A2 Method for the preparation of organic acids via oxidization using nitric acid |
| 02/21/2008 | US20080045705 2-oxoethyl(1R)-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-[[3,5-dimethyl-4-(phenylmethoxy)phenyl]methyl]-2-[4-(4-morpholinyl)-1-piperidinyl]-1-piperidinecarboxylate; coupling alpha -hydroxy-3,5-dimethyl-4-(phenylmethoxy)-phenylpropionic acid-monosodium salt with 1,3-benzodiazepin compound |
| 02/21/2008 | US20080045597 Dissolves quickly and completely in variety of foods and beverages without negatively impacting taste or texture; bone nutraceutical support |
| 02/21/2008 | US20080045596 Ep2 Receptor Agonists |
| 02/21/2008 | DE102006039038A1 Neues Herstellungsverfahren New manufacturing process |
| 02/21/2008 | DE102006026000A1 Binder for calcium phosphate or glass-ceramic particles, useful for producing bone reconstruction materials, comprises an aqueous or alcoholic solution of a carboxylic acid |
| 02/21/2008 | CA2660389A1 Method for the preparation of organic acids via oxidization using nitric acid |
| 02/20/2008 | EP1888505A1 Organic compounds |
| 02/20/2008 | EP1888499A1 A process for the dynamic resolution of (substituted) (r) - or (s) -mandelic acid |
| 02/20/2008 | CN101125813A Method for synthesizing allyl cyclohexoxyacetate |
| 02/20/2008 | CN100369891C HIF hydroxylase inhibitors |
| 02/20/2008 | CN100369887C Inhibitors of oleamide hydrolase |
| 02/20/2008 | CN100369882C Technological process of purifying and refining glyoxylic acid |
| 02/19/2008 | US7332631 Fc receptor modulating compounds and compositions |
| 02/19/2008 | US7332085 Method for the purification of an α-hydroxy acid on an industrial scale |
| 02/14/2008 | WO2008018520A1 Method for producing optically active hydroxycarboxylic acid derivative or salt thereof |
| 02/14/2008 | US20080039636 4-substituted 7-hydroxy-coumarin derived compounds as effective cosmetic agents, particularly, skin lightening agents; cost efficient, simple to produce |
| 02/13/2008 | EP1885682A2 P-tert-butylcalix[6]arenes with triacidic functions at 2, 4 and 6 supported liquid membranes support materials comprising the same and use thereof |
| 02/13/2008 | EP1885680A1 Process for the preparation of adamantane derivatives |
| 02/13/2008 | EP1667960B1 Meldonium salts, method of their preparation and pharmaceutical composition on their basis |
| 02/13/2008 | CN100368375C 3- alkoxy -4-carbalkoxyphenylacetate and 3-alkoxy-4-carbalkoxyphenylacetic acid synthesis method |
| 02/13/2008 | CN100368374C Carboxylic compound and medicine comprising the same |
| 02/13/2008 | CN100368373C Carboxyl substituted resveratrol analog compound and its preparation method |
| 02/12/2008 | US7329782 Compounds for the treatment of metabolic disorders |
| 02/12/2008 | US7329759 1-Substituted-[1H-indene-6,1'-cyclopropane]-4-one derivatives: solid tumors and multi-drug resistant tumors; may also be targeted to a particular tumor; can either be cytostatic or cytotoxic to the tumor cells |
| 02/07/2008 | WO2008015885A1 Method for purifying hydroxycarboxylic acid, method for producing cyclic ester, and method for producing polyhydroxycarboxylic acid |
| 02/07/2008 | US20080032982 2-{2-[3-(4-chlorophenyl)acryloyl]-4-methylphenoxy}-4-phenylbutanoic acid; Peroxisome Proliferator Activated Receptors (PPAR); diabetes, dyslipidemia and/or atherosclerosis |
| 02/07/2008 | US20080032893 Salts of Dihydrojasmonic Acid and Use Thereof in Agriculture |
| 02/07/2008 | US20080032370 Process for Producng Hydroxycarboxylic Acid |
| 02/06/2008 | CN101119951A Modulator |
| 02/06/2008 | CN101117333A Catalytic depolymerization of polymers containing electrophilic linkages using nucleophilic reagents |
| 02/06/2008 | CN101117316A Oral liquid for preventing and remitting diabetes |
| 02/06/2008 | CN101117315A Production method of lemon acid |
| 02/06/2008 | CN101117314A Production method of sodium citrate |
| 02/06/2008 | CN101117304A Method for proceeding asymmetric catalytic hydrogenation reaction |
| 01/31/2008 | WO2008011651A1 Method for the production of lactic acid or a salt thereof |
| 01/31/2008 | US20080027229 Compounds for the treatment of metabolic disorders |
| 01/31/2008 | US20080027096 Novel Pharmaceutical Compositions |
| 01/30/2008 | CN101113134A Triterpenes anti-neoplastic compound in cambric asterism sponge and method for preparing the same |
| 01/30/2008 | CN100364991C Crystals including a malic acid salt of a 3-pyrrole substituted 2-indolinone, and compositions thereof |
| 01/30/2008 | CN100364952C Process for hydrothermal synthesizing bismuth citrate |
| 01/29/2008 | US7323591 7-[(1R,2S,3R,5R)-2-(3,5-Bis-trifluoromethyl-phenoxymethyl)-5-chloro-3-hydroxy-cyclopentyl]-heptanoic acid; glaucoma and/or ocular hypertension |
| 01/29/2008 | US7323587 Selective estrogen receptor modulators |
| 01/29/2008 | US7323201 Highly soluble form of tricalcium citrate, and methods of its making and use |
| 01/24/2008 | US20080021109 5-[3-(2,6-Dimethylbenzyloxy)-phenyl]-pent-4-enoic acid ethyl ester; insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis, arteriosclerosis; side effects reduction; orally active |
| 01/24/2008 | US20080021088 Retinoid Derivatives With Antiangiogenic, Antitumoral And Proapoptotic Activities |
| 01/24/2008 | US20080020963 11-Methyl-13-Tridecanolide, 12-Methyl-14-Tetradecanolide And 13-Methyl-15-Pentadecanolide, Perfume Compositions Containing The Same, And Process For Production Of Compounds Including The Same |
| 01/23/2008 | EP1879562A2 Phenol derivatives and their use to modulate pkb activity |
| 01/23/2008 | CN100363410C Catalytic depolymerization of polymers containing electrophilic linkages using nucleophilic reagents |
| 01/22/2008 | US7321059 2,3-diethoxylated propionic acid derivatives, e.g., 20-(7,10,13,16-tetraoxaheptadec-1-yloxy)-2,5,8,11,18-pentaoxahenicosan-21-oic acid; for use in inhalation therapy with propellants for treating respiratory system disorders |
| 01/22/2008 | US7321046 Analogs of dictyostatin, intermediates therefor and methods of synthesis thereof |
| 01/22/2008 | US7321044 Synthesis of oxygen-substituted benzocycloheptenes as valuable intermediate products for the production of tissue-selective estrogens |
| 01/17/2008 | WO2008008718A2 Cyclopentane derivatives as antiglaucoma agents |
| 01/17/2008 | WO2008008660A2 Cyclopentane derivatives as antiglaucoma agents |
| 01/17/2008 | WO2008007497A1 Aqueous solutions of organic acid chromium(iii) salts and process for preparation thereof |
| 01/17/2008 | US20080015258 Dissolving moprolol and tartaric acid in a 2:1 molar ratio in ethanol, precipitating and filtering; gels ointments, eyedrops; glaucoma; improved tolerability over hydrochloride salt |
| 01/17/2008 | US20080015254 5-[3-(2,6-Dimethylbenzyloxy)-phenyl]-pent-4-enoic acid ethyl ester; insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis, arteriosclerosis; side effects reduction; orally active |
| 01/17/2008 | US20080015253 Peroxisome Proliferator Activated Receptors modulators; ethyl (R,S)-2-(4-trifluoromethylphenyl)oxypent-4-enoate; dyslipidemia, atherosclerosis and diabetes |
| 01/17/2008 | US20080015219 Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; acid-functional aryl substituted cyclopentanone or hydroxycyclopentane compounds |
| 01/17/2008 | US20080015209 Compounds for the treatment of metabolic disorders |
| 01/17/2008 | US20080014642 Tagging reagents and methods for hydroxylated compounds |
| 01/17/2008 | US20080014307 calcium fortify beverages such as fruit juices, or foods; has an X-ray powder diffraction pattern comprising peaks at 2-theta (2 theta ) values of about 8.236, about 16.02, about 17.97, about 19.75, about 21.42, about 25.74, and about 28.65; dissolved in a beverage; dispersed in a food |
| 01/17/2008 | US20080014304 Amorphous Water-Soluble Calcium Citrate Salts and Method of Making and Using Same |
| 01/17/2008 | CA2659121A1 Therapeutic compounds |